Australian biomedical research efforts boosted by $10.4 million
3 September 2020 Congratulations to all BioMelbourne Network member organisations that received funding, including BARD1 Life Sciences Limited, The Florey Institute of Neuroscience and Mental Health, Dimerix Bioscience Pty Ltd, LBT Innovations Ltd, Starpharma Holdings Ltd and University of Melbourne. Learn more about the funded projects.…
‘Chance favours the prepared mind’ – Frederico Calhabeu has followed Louis Pasteur’s advice from France to Cartherics
3 September 2020 Originally posted by Catherics. When considering whether to continue his translational research program at the Australian Regenerative Medicine Institute (ARMI), Frederico Calhabeu had a quick chat with Silvio Tiziani, Director, External Strategy and Planning at…
Protein discovery could improve type 2 diabetes treatment
3 September 2020 A world first discovery of how a protein works in the liver could lead to a more effective type 2 diabetes drug. The researchers say such treatments will be more important than ever given that…
Good News from Cartherics: New funding from the Federal Entrepreneurs Programme will boost the company’s R&D efforts
3 September 2020 “It’s good to get new money into Cartherics,” says the Cartherics’ Chief Scientific Officer Richard Boyd. He adds that the AU$120,000 in grant funding is particularly welcome as all Melbourne-based research and development (R&D) groups…
3 new La Trobe COVID-19 projects begin
3 September 2020 Release date 28 August 2020 La Trobe University researchers are rapidly embarking on ways to improve community health and wellbeing as a result of the COVID-19 pandemic, with new targeted grants from La Trobe, Medibank…
Starpharma creates slow release soluble DEP® remdesivir nanoparticle
1 September 2020 DEP® remdesivir has been created to expand the potential application of remdesivir, by creating a long-acting version which could be administered subcutaneously rather than by intravenous infusion in hospital DEP® remdesivir is a highly water-soluble nanoparticle formulation…
Trillion data points to identify disease-causing genes
1 September 2020 Researchers from CSIRO, Australia’s national science agency, have accomplished a world-first by processing one trillion points of genomic data through VariantSpark, an artificial intelligence-based platform, which can help pinpoint the location of specific disease-causing genes…
Breakthrough discovery paves the way for preventing sugar-induced liver disease
3 September 2020 Release date 25 August 2020 A team of international researchers including Monash University academics has discovered that, contrary to previous belief, fructose causes liver toxicity by changing the barrier function of the intestine. This new…
Nucleus Network begins dosing for third COVID-19 vaccine trial
1 September 2020 Australia’s largest Phase 1 Clinical trials specialist, Nucleus Network, has today commenced dosing the first human participants for the Phase 1/2 trial COVID-19 Vaccine trial in collaboration with the vaccine’s developer Serum Institute of India…
Living with COVID-19 – an assessment of the pandemic’s ongoing impact on Australian Healthcare (IQVIA)
Date posted 1 September 2020 IQVIA ANZ business has just released; Living with COVID-19 – an assessment of the pandemic’s ongoing impact on Australian Healthcare. This is the second in a special series of reports, which offer IQVIA’s…
Luina Bio announces new Bio-manufacturing GMP and development facility expansion
1 September 2020 Highlights Small scale GMP manufacturing suites open in Q3 2020 500L tech transfer and process development site aim for open Q4 2020 This precedes the next phase with Luina planning to commission a 10,000m2 late…
4DMedical Release FY20 Full Year Results
1 September 2020 Release date 28 August 2020 4DMedical Limited, a medical technology company focused on commercialising its patented respiratory imaging technology, today announces its full year results for the financial year ended 30 June 2020 (FY20). During…
